Biosimilars and the extrapolation of indications for inflammatory conditions.
about
Tumor necrosis factor-alpha inhibitors and risk of non-Hodgkin lymphoma in a cohort of adults with rheumatologic conditionsThe surge in biosimilars: considerations for effective pharmacovigilance and EU regulationFood and Drug Administration guidances on biosimilars: an update for the gastroenterologist
P2860
Biosimilars and the extrapolation of indications for inflammatory conditions.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Biosimilars and the extrapolation of indications for inflammatory conditions.
@en
type
label
Biosimilars and the extrapolation of indications for inflammatory conditions.
@en
prefLabel
Biosimilars and the extrapolation of indications for inflammatory conditions.
@en
P2093
P2860
P356
P1476
Biosimilars and the extrapolation of indications for inflammatory conditions.
@en
P2093
Daniel E Furst
Ira Jacobs
John Rp Tesser
P2860
P356
10.2147/BTT.S124476
P577
2017-02-17T00:00:00Z